Applied Genetic Technologies Corporation  (AGTC)
Other Ticker:  
Price: $0.3936 $0.00 1.235%
Day's High: $0.4 Week Perf: 4.76 %
Day's Low: $ 0.37 30 Day Perf:
Volume (M): 765 52 Wk High: $ 0.00
Volume (M$): $ 301 52 Wk Avg: $0.00
Open: $0.37 52 Wk Low: $0.00

 Market Capitalization (Millions $) 26
 Shares Outstanding (Millions) 65
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -70
 Cash Flow (TTM) (Millions $) -53
 Capital Exp. (TTM) (Millions $) 2

Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation (AGTC) is a biotechnology company that develops gene therapies to treat genetic disorders. The company utilizes its expertise in the field of adeno-associated virus (AAV) vectors to deliver genes to specific cells and tissues in the body. AGTC focuses on developing treatments for rare ophthalmic diseases, including inherited retinal disorders, such as X-linked retinoschisis and achromatopsia. The company's goal is to improve the quality of life for patients suffering from these disorders by providing effective and long-lasting gene therapies. AGTC is committed to advancing the field of gene therapy and conducting clinical trials to evaluate the safety and efficacy of its treatments.

   Company Address: 14193 NW 119th Terrace, Suite 10 Alachua 32615 FL
   Company Phone Number: 462-2204   Stock Exchange / Ticker: NASDAQ AGTC


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc Struggles with Financial Losses in Fourth Quarter of 2023: A Closer Look at the TechBio Company's Fiscal Performance

Recursion Pharmaceuticals Inc, a leading clinical stage TechBio company focused on decoding biology for drug discovery, has reported its financial results for the fourth quarter and fiscal year ending December 31, 2023. The company's weak business performance led to a rise in losses for the most recent fiscal period. It experienced a shortfall per share of $-0.35, compared to $-0.30 in the previous year, while its revenue declined by 20.364% to $10.89 million from $13.68 million.
However, the third quarter showed some positive signs for Recursion Pharmaceuticals Inc, with revenue growth of 3.399% from $10.53 million and an improvement in earnings per share from $-0.43 per share. But for the most recent fiscal period, the company incurred a net loss of $-92.996 million, which was larger than the $-57.492 million loss recorded in the previous year.

Vericel Corporation

elevation, elevation, elevation by in the most recent fiscal period

Adma Biologics Inc

Adma Biologics Inc Sees Enlarged Diminishing Returns in Fourth Quarter Financial Report

Adma Biologics Inc, a biopharmaceutical company specializing in plasma-derived antibody products, has reported a deficit per share of $-0.07 in the fourth quarter of 2023, an increase from the previous quarter. However, the company's revenue saw a significant uptick of 49.427% to $74.69 million compared to the same period the year before. This revenue growth comes as a positive surprise amidst a -4.90% contraction in the Biotechnology and Pharmaceuticals sector.
The company's net deficit for the financial interval closing December 31, 2023, was $-17.645 million, a larger figure than the previous year. Additionally, Adma Biologics Inc saw an increase in inventories to $172.9 million, as well as a decline in accounts receivable to $27.4 million. For the full year of 2023, the company reported a net deficit of $-28.24 million and revenue of $257.94 million.

Voyager Therapeutics Inc

Headline: Voyager Therapeutics Inc Surges in Financial Fourth Quarter of 2023

Investors in Voyager Therapeutics Inc (Nasdaq: VYGR) have reason to celebrate as the biotechnology company has turned around its financial performance in the most recent fiscal period. With Income per Share at $1.06 per share, VYGR has shown significant improvement compared to previous reporting periods. Revenue has also doubled by a staggering 1851.907% from the preceding reporting season, leading to a positive net earnings of $56.395 million in the financial fourth quarter of 2023.
The company's focus on improving sales has resulted in a net margin of 62.62% in the financial fourth quarter of 2023, further solidifying its profitability. In the fiscal year 2023, VYGR reported earnings per share of $2.97, a significant increase from the previous fiscal year.

Iovance Biotherapeutics Inc

Financial Challenges Amidst Innovation: Iovance Biotherapeutics Reports Revenue of $0.482 Million for Q4 2023

Iovance Biotherapeutics Inc, a leading biotechnology company, recently announced its financial results for the fourth quarter of 2023. The company reported revenue of $0.482 million for the quarter, with a net shortfall of $-116.379 million. This shortfall was larger than the $-105.319 million reported in the same quarter a year ago, indicating a significant increase in expenses for the company. Additionally, Iovance Biotherapeutics reported a net deficit of $-444.04 million for the fiscal year 2023, with total revenue reaching $1.19 million.
Despite these financial challenges, Iovance Biotherapeutics has made significant progress in advancing its novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The company recently announced FDA approval for one of its therapies, demonstrating its commitment to innovation and improving patient outcomes.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com